Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

We evaluated the efficacy of metronomic etoposide or temozolomide administered with bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior bevacizumab therapy in a phase 2, open-label, two-arm trial. Twenty-three patients received bevacizumab (10 mg/kg) every 2 weeks with ei...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Reardon, David A., Desjardins, Annick, Peters, Katherine, Gururangan, Sridharan, Sampson, John, Rich, Jeremy N., McLendon, Roger, Herndon, James E., Marcello, Jennifer, Threatt, Stevie, Friedman, Allan H., Vredenburgh, James J., Friedman, Henry S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102515/
https://ncbi.nlm.nih.gov/pubmed/20853132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0403-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados